[16]Arnold D，Reinacher-Schick A，Muller J，et al. Bevacizumab (Bev) beyond progression (BP) in combination with second-line chemotherapy (CT) after failure of a Bev containing first-line CT in patients (pts) with metastastic colorectal cancer (mCRC). Preliminary baseline and safety analysis from the AIO 0504/AGMT phase III study[A].2008 Gastrointestinal Cancers Symposium[C].2008：Abstract No 469.

    [17]van Cutsem E ......